Insider Buying: CVS Health (NYSE:CVS) EVP Acquires 23,855 Shares of Stock

CVS Health Corporation (NYSE:CVS) EVP Prem Shah purchased 23,855 shares of the business’s stock in a transaction dated Friday, November 6th. The shares were purchased at an average price of $83.89 per share, for a total transaction of $2,001,195.95. Following the acquisition, the executive vice president owned 88,516 shares of the company’s stock, valued at approximately $7,425,607.24. The trade was a 36.89% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

CVS Health Stock Up 3.0%

Shares of CVS traded up $2.43 on Friday, hitting $83.76. 14,033,340 shares of the stock traded hands, compared to its average volume of 8,542,881. CVS Health Corporation has a one year low of $69.51 and a one year high of $110.68. The company has a market capitalization of $107.12 billion, a PE ratio of 9.75, a P/E/G ratio of 0.73 and a beta of 0.58. The business has a 50 day simple moving average of $90.56 and a 200 day simple moving average of $88.87. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.66 and a current ratio of 0.85.

CVS Health (NYSE:CVS) last released its quarterly earnings data on Wednesday, November 4th. The pharmacy operator reported $2.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.65 by $0.44. CVS Health had a return on equity of 13.65% and a net margin of 2.62%. The business had revenue of $108.40 billion for the quarter, compared to analysts’ expectations of $104.72 billion. During the same period in the prior year, the firm posted $1.60 EPS. The firm’s quarterly revenue was up 5.4% on a year-over-year basis. As a group, equities analysts forecast that CVS Health Corporation will post 8.20 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, November 2nd. Stockholders of record on Thursday, October 22nd were issued a dividend of $0.6650 per share. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.2%. The ex-dividend date of this dividend was Thursday, October 22nd. CVS Health’s dividend payout ratio is presently 30.97%.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Allworth Financial LP grew its position in CVS Health by 189.7% during the third quarter. Allworth Financial LP now owns 96,237 shares of the pharmacy operator’s stock valued at $8,247,000 after buying an additional 63,022 shares during the period. Fisher Asset Management LLC raised its position in CVS Health by 6.4% in the third quarter. Fisher Asset Management LLC now owns 97,886 shares of the pharmacy operator’s stock worth $8,388,000 after acquiring an additional 5,876 shares during the period. Eurizon Capital SGR S.p.A. boosted its stake in shares of CVS Health by 256.6% during the 3rd quarter. Eurizon Capital SGR S.p.A. now owns 322,035 shares of the pharmacy operator’s stock worth $27,631,000 after acquiring an additional 231,740 shares during the last quarter. Werba Rubin Papier Wealth Management boosted its stake in shares of CVS Health by 10.9% during the 3rd quarter. Werba Rubin Papier Wealth Management now owns 3,427 shares of the pharmacy operator’s stock worth $294,000 after acquiring an additional 337 shares during the last quarter. Finally, Endeavor Private Wealth Inc. grew its position in shares of CVS Health by 13.9% during the 3rd quarter. Endeavor Private Wealth Inc. now owns 3,642 shares of the pharmacy operator’s stock valued at $312,000 after acquiring an additional 445 shares during the period. 80.66% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS beat third-quarter earnings and revenue expectations and raised its 2026 outlook, with management citing improvement at Aetna. These stronger fundamentals offer support for the shares. CVS Health Q3 Earnings Call Focuses on Planned Pharmacy Separation
• Positive Sentiment: The planned separation, targeted for 2028, could let investors value the retail pharmacy business and the insurance/health-services businesses separately. Some investors see potential for the move to unlock value, although the outcome depends on the details. CVS Health: The Breakup Puts A Price On The Pharmacy
• Neutral Sentiment: UBS and Leerink lowered their price targets but kept Buy/Outperform ratings, while Barclays also trimmed its target and maintained an Overweight rating—suggesting continued optimism alongside more cautious valuation assumptions. UBS price-target update
• Negative Sentiment: The breakup announcement triggered a sharp selloff in recent trading, as CVS has not yet provided key details on structure, costs, or how the businesses will operate separately. That uncertainty has overshadowed the earnings beat and may keep pressure on the stock until investors can assess the plan. Why CVS stock fell after raising its outlook and announcing a breakup
• Negative Sentiment: Reports that CVS lost ground on Medicare ratings raise concern about Aetna’s competitive position and potential effects on its Medicare business. Separately, AM Best placed ratings for Aetna subsidiaries under review with developing implications amid the planned separation, adding to uncertainty. CVS and UnitedHealth lost ground on Medicare ratings

Analyst Ratings Changes

Several equities research analysts recently commented on CVS shares. TD Cowen reiterated a “buy” rating on shares of CVS Health in a report on Wednesday. BMO Capital Markets set a $112.00 target price on shares of CVS Health in a research note on Wednesday, September 9th. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of CVS Health in a report on Friday, October 9th. Truist Financial lifted their price target on shares of CVS Health from $108.00 to $118.00 and gave the stock a “buy” rating in a research note on Tuesday, July 14th. Finally, Weiss Ratings cut shares of CVS Health from a “buy (b-)” rating to a “hold (c+)” rating in a report on Friday, October 9th. Twenty-two research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $108.25.

CVS Health Company Profile

CVS Health is a U.S.-based health care company that operates retail pharmacies, provides pharmacy benefit management services, and offers health insurance and other health services. Its businesses include CVS Pharmacy, pharmacy benefit manager CVS Caremark, and Aetna, its health benefits division.

The company also provides care through MinuteClinic walk-in clinics and health care businesses including Oak Street Health and Signify Health. Its services span prescription fulfillment, pharmacy benefit management, health insurance, primary care, and in-home and community-based care.

Founded in 1963 as Consumer Value Stores in Lowell, Massachusetts, the company expanded from a retail pharmacy business into a broad health care organization and adopted the CVS Health name in 2014.